BCL2 and acute myeloid leukemia: It is possible that CR-1-31-B-mediated reduction of BCL2 and family members MCL1 and BCL-XL contributes to the synergistic effect, since MCL1 was shown to contribute to venetoclax resistance, both in preclinical models in vivo and in AML patients [10, 66].